Compare CPRX & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPRX | PBLS |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | 2006 | 2026 |
| Metric | CPRX | PBLS |
|---|---|---|
| Price | $31.47 | $30.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 570.4K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.24 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $119,072,803.00 | N/A |
| Revenue This Year | $9.20 | N/A |
| Revenue Next Year | $10.51 | N/A |
| P/E Ratio | $62.94 | ★ N/A |
| Revenue Growth | ★ 16.39 | N/A |
| 52 Week Low | $19.05 | $25.56 |
| 52 Week High | $32.56 | $31.51 |
| Indicator | CPRX | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 70.25 | 63.88 |
| Support Level | $31.25 | $26.68 |
| Resistance Level | $32.56 | N/A |
| Average True Range (ATR) | 0.04 | 2.34 |
| MACD | -0.07 | 0.29 |
| Stochastic Oscillator | 86.67 | 78.51 |
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.